Clinical trial

Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors

NCT05797168

StatusRECRUITING

Study typeINTERVENTIONAL

Start date2023-06-05

PhasePHASE1 / PHASE2

Study timeline

Study start (actual)2023-06-05Date precision: day

Registry last updated2026-10-05

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Ovarian Cancerunresolved

Lung Adenocarcinomaunresolved

Endometrial Cancerunresolved

Lung Squamous Cell Carcinomaunresolved

Interventions

Torvutatug samrotecanDRUG

BevacizumabDRUG · verified · RxNorm: bevacizumab

CarboplatinDRUG · verified · RxNorm: carboplatin

PalacaparibDRUG

PembrolizumabDRUG · verified · RxNorm: pembrolizumab

Sponsors & collaborators

AstraZenecalead sponsor

Mapped research locations

AnkaraTurkey (Türkiye)3 SeoulSouth Korea2 MadridSpain2 LondonUnited Kingdom2 MontrealQuebec, Canada2 TaipeiTaiwan2 ProvidenceRhode Island, United States2 GuangzhouChina2 HoustonTexas, United States1 BostonMassachusetts, United States1 TorontoOntario, Canada1 BarcelonaSpain1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT05797168 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.